All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1400+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Business Development

Zymeworks lands $25M milestone payment from Jazz Pharmaceuticals for Ziihera (dual HER2-targeting)
Bispecific antibody, biliary tract cancer - Read more

Transposon Therapeutics buys novel nucleoside analog portfolio (nucleoside reverse transcriptase inhibitors) from PrimeFour Therapeutics
Small molecule, neurodegenerative disease, autoimmune - Read more

Genprex buys worldwide patents rights to University of Michigan’s combination of Reqorsa gene therapy + ALK-inhibitors as potential lung cancer treatment
Gene therapy, lung cancer, small molecule - Read more

Ayrmid buys ex-Asia, non-solid tumor indication rights to Aphexda (CXCR4 inhibitor) from BioLineRx
Peptide, multiple myeloma, stem cell mobilization agent - Read more

THE GOOD
Clinical Trials

DP Technology, Lepu Biopharma head to the clinic with first AI-designed ADC candidate
Antibody-drug conjugate, cancer - Read more

argenx opts for continuing Ph2/3 efgartigimod SC (neonatal Fc receptor targeting) following analysis of topline Ph2 data
Fc fragment, idiopathic inflammatory myopathies, myositis - Read more

Neuralink ok’d by Health Canada to begin Canadian clinical trials
Medical device, brain-computer interface - Read more

THE GOOD
Company Launches

Pep2Tango Therapeutics (a Versant Ventures company) launches with unspecified “double-digit” millions and and 4-in-1 obesity management plan
GLP-1, obesity - Read more

Aizen Therapeutics launches with $13M Seed raise and AI-enabled mirrored amino acid ambitions
Small molecule, amino acids - Read more

THE GOOD
Earnings & Finances

Novartis bullish on growth ambitions, pins 6% CAGR through 2028 (1% more than previously stated) driven by new cancer, immunology meds
Big pharma earnings, cancer, immunology - Read more

PRESENTED BY YOU?
Get the attention of 1400+ Biotech & Pharma Professionals 🤩

Looking to promote your biotech/pharma/life science-focused product or service to a captivated audience of industry professionals?

(Or get the attention of analysts/investors operating in this space?)

Consider sponsoring TLDR Biotech - your sponsored feature would go right here!

If you want to see our prospectus or if you’re ready to work with us, just reply to this email or message me on LinkedIn.

⬇️ More Good News ⬇️

THE GOOD
Fundraises

OneCell Diagnostics $16M Series A, genomics-based precision oncology
Cancer screening, bioinformatics, AI/ML, multi-omics - Read more

TearSolutions $3M Series B, a “potentially disruptive” ocular surface related disease solution
Peptide, Ocular Surface Disease - Read more

GenEdit KRW 47.3B ($35M) Series B, gene delivery platform
Immunotherapy, gene delivery platform, drug delivery - Read more

Enveda $130M Series C, advance pipeline and drug discovery platform
Small molecule, atopic dermatitis, natural product drug discovery, AI - Read more

Cidara Therapeutics $105M private placement
Drug-Fc conjugate, influenza, oncology, cancer - Read more

Lineage Cell Therapeutics $66M director offering
Cell therapy, geographic atrophy, age-related macular degeneration, auditory neuropathy, off-the-shelf - Read more

Verrica Pharmaceuticals $42M public offering
Small molecule, molluscum contagiosum, carcinoma, cancer - Read more

THE GOOD
Mergers & Acquisitions

Novartis bets big on neuromuscular gene therapies with up to $1.1B purchase of Kate Therapeutics
Gene therapy, duchenne muscular dystrophy, X-linked myotubular myopathy - Read more

H.I.G. Capital offloads automated drug/medical device distribution system maker DeeNova to Ersel Asset Management and Amundi Private Equity
Pharmaceutical distribution, traceability, robotics - Read more

THE GOOD
Partnerships

Kyowa Kirin, Kura Oncology global development, commercialization collab for ziftomenib (menin inhibitor)
Small molecule, leukemia, cancer - Read more

CStone, Pharmalink strategic Middle East & North Africa region and South Africa commercialization partnership for sugemalimab (anti-PD-L1 IgG4)
Monoclonal antibody, cancer - Read more

Zai Lab, Pfizer partner on Xacduro (targeting carbapenem-resistant Acinetobacter baumannii) commercialization in mainland China
Small molecule, bacterial pneumonia, anti-infective - Read more

PCI Pharma Services, ChiRhoClin partner on preventing pancreatic disease/cancer diagnostic agent shortages
Peptide, pancreatic cancer, pancreatic diseases, diagnostics - Read more 

THE GOOD
Politics & Policy

Pharma ads might be in the crosshairs as RFK Jr. rides into the HHS (with Elon riding shotgun)
Pharma advertising - Read more

Trump’s FDA head appointee might be a surgeon, who’s ok with vaccines up to a point
FDA commissionner appointment - Read more

THE GOOD
Public Health

CBER’s Peter Marks keeps things positive on upcoming “vigorous” vaccine dialogues, says this might not be “a bad thing”
Vaccines, infectious disease - Read more

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech🧬🦠🔬 

I’m offering this newsletter for free so it can get out to as many people as possible.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.*

*Best of all, it’s a work-related news source that you can likely expense. 😉 

THE BAD
Approvals & Labels

As expected, AstraZeneca’s Andexxa accelerated-to-full approval bid doesn’t inspire much confidence amongst FDA adcom members
Recombinant coagulation factor, bleeding reversal - Read more

THE BAD
Clinical Trials

Pyxis Oncology’s PYX-201 (extradomain-B fibronectin inhibitor) ADC’s Ph1 data sent investors scrambling and the stock falling, though some analysts consider it an overreaction
Antibody-drug conjugate, solid tumor, cancer - Read more

THE BAD
Layoffs

Sonata Therapeutics drops 20 employees and current CEO
Network medicines, pancreatic cancer, colorectal cancer - Read more

HOOPIKA Pharma cuts a whopping 80% of staff, halts clinical development of one clinical (in HPV16+ head-and-neck cancers) while continuing with two others
Vaccine, hepatitis B, human immunodeficiency virus, human papillomavirus - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here